New publication: Antimicrobial activity of M33

Antimicrobial activity of levofloxacin – M33 peptide conjugation or combination


M33 is a branched peptide currently under preclinical characterization for development as a new drug against Gram-negative bacteria. Here we report its antibacterial activity in conjugation or combination with levofloxacin (LVFX), a fluoroquinolone antibiotic. Antibacterial assays showed no significant differences in activity when used in conjugation, while the combination of M33 and LVFX showed improved activity against Gram-negative bacteria. Combination treatment therefore opposes antimicrobial-resistance, restoring the effect of LVFX.



Federica Ceccherini (SetLance srl), Chiara Falciani (SetLance srl), Martina Onori (SetLance srl),  Silvia Scali (University of Siena), Simona Pollini (University of Siena), Gian Maria Rossolini (University of Siena, University of Florence, Florence Careggi University Hospital), Luisa Bracci (University of Siena, Siena University Hospital) and   Alessandro Pini (University of Siena, Siena University Hospital)


Med. Chem. Commun., 2016, Advance Article, DOI: 10.1039/C5MD00392J


Read more PneumoNP news

Meeting in Maastricht

PneumoNP: Exciting 6-month race ahead

With only six months to go before its end, the PneumoNP consortium gathered once more for their penultimate progress meeting ...
Read More

Meet us at EuroNanoForum 2017

Iraida Loinaz, coordinator of the PneunoNP project, attends the EuroNanoForum 2017 conference. EuroNanoForum 2017 is an international event that focus ...
Read More

Confront antibiotic resistance with a better diagnostic system

To slow down the rise of non-curable infections, a Dutch company developed a diagnostic kit to identify strains of antibiotic-resistant ...
Read More